Phaseline

Companies › Aphaia Pharma US

Aphaia Pharma US: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APHD-002
Distal jejunal-release dextrose beads
–Phase 2Obese With Comorbidities–
APHD-012
Distal jejunal-release dextrose beads
–Phase 2Obese With Comorbidities–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07008456APHD-012Phase 2Obese With ComorbiditiesMetabolic and endocrineJul 2026
NCT07008456APHD-002Phase 2Obese With ComorbiditiesMetabolic and endocrineJul 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Portal Therapeutics Op-T Housey Healthcare ULC

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.